Table 1.
Characteristics of the included trials
| Author | Year | Country | Study | Disease status | Enrollment period | Phase | Median follow-up (months) | Lenalidomide/control group | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Regimen | Median age (range) | Female/Male | ||||||||
| Czuczman et al. [19] | 2017 | America | DLC-001 | R/R | – | II/III | – | LEN | 69 (28–84) | 21/30 |
| Investigator’s Choice | 65 (20–84) | 20/31 | ||||||||
| Thieblemont et al. [20] | 2017 | France | REMARC | Untreated | 2009.05–2014.05 | III | 52 | LEN | 69 (58–80) | 140/183 |
| Placebo | 68 (59–80) | 147/180 | ||||||||
| Kühnl et al. [21] | 2020 | UK | LEGEND | R/R | 2013.10–2016.11 | II | 21.5 for living pts | LEN+R-GEM | 58 (21–75) | 8/13 |
| R-GEM-P | 59 (21–77) | 5/14 | ||||||||
| Nowakowski et al. [22] | 2021 | America | ECOG-ACRIN E1412 | Untreated | 2013.08–2017.01 | II | 36 | LEN+R-CHOP | 67 (24–88) | 51/94 |
| R-CHOP | 66 (37–92) | 59/76 | ||||||||
| Oberic et al. [23] | 2021 | France | SENIOR | Untreated | 2014.08–2017.09 | III | 25.1 | LEN+R-MiniCHOP | ≥ 80 | 65/57 |
| R-MiniCHOP | ≥80 | 71/56 | ||||||||
| Nowakowski et al. [24] | 2021 | America | ROBUST | Untreated | 2015.02–2017.08 | III | 27.1 (0–47) for living pts | LEN+R-CHOP | 65 (21–82) | 121/164 |
| Placebo+R-CHOP | 65 (28–83) | 142/143 | ||||||||
R/R relapsed/refractory, LEN lenalidomide, pts: patients, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-GEM rituximab, methylprednisolone and gemcitabine, R-GEM-P rituximab, methylprednisolone, gemcitabine, cisplatin, R-MiniCHOP standard attenuated dose of R-CHOP